Cargando…
The presence of elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation.
Biopsy samples of head and neck carcinomas were investigated with regard to elafin, secretory leukocyte protease inhibitor (SLPI), interleukin 1-receptor antagonist [(IL)1-RA] and soluble tumour necrosis factor alpha receptor antagonist (STNFalpha RI). SLPI and elafin are serine protease inhibitors...
Autores principales: | Westin, U, Nyström, M, Ljungcrantz, I, Eriksson, B, Ohlsson, K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781642/ https://www.ncbi.nlm.nih.gov/pubmed/11926597 |
Ejemplares similares
-
Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells.
por: Nyström, M, et al.
Publicado: (1999) -
Differential effects of periopathogens on host protease inhibitors SLPI, elafin, SCCA1, and SCCA2
por: Yin, Lei, et al.
Publicado: (2010) -
Secretory Leukocyte Protease Inhibitor (SLPI) Is, like Its Homologue Trappin-2 (Pre-Elafin), a Transglutaminase Substrate
por: Baranger, Kévin, et al.
Publicado: (2011) -
Human mast cells decrease SLPI levels in type II – like alveolar cell model, in vitro
por: Hollander, Camilla, et al.
Publicado: (2003) -
IgE-mediated histamine release from nasal mucosa is inhibited by SLPI (secretory leukocyte protease inhibitor) to the level of spontaneous release.
por: Westin, U, et al.
Publicado: (1998)